°øÁö»çÇ×

HOME > ÇÐȸ¼Ò°³   >   °øÁö»çÇ×

2007³â Á¦13Â÷ ¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç ¿¬¼ö°­ÁÂ
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
÷ºÎÆÄÀÏ
ÀÛ¼ºÀÏ
2007-03-05
Á¶È¸
7507
2007³â Á¦13Â÷ ¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç ¿¬¼ö°­ÁÂ

¡Þ¸ð½Ã´Â ±Û¡Þ

Ç÷¾×Á¾¾çÇÐ ¿¬¼ö°­Á¿¡ ÁîÀ½ÇÏ¿©

±Þº¯ÇÏ°í ÀÖ´Â Çö´ë ÀÇÇп¡ ´ëóÇÏ°í ÀÇ·á¼öÁØÀÇ Áö¼ÓÀûÀÎ Çâ»óÀ» À§ÇÏ¿© ÀÇ·áÀο¡ ´ëÇÑ Æò»ý±³À°ÀÇ Á߿伺Àº ¿ì¸® ¸ðµÎ°¡ ÁÖÁöÇÏ°í ÀÖ´Â »ç½ÇÀÔ´Ï´Ù. ÀÌ·± ¸ñÀûÀ» ´Þ¼ºÇϱâ À§ÇÏ¿© ¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ¹× º´¿ø¿¡¼­´Â Çظ¶´Ù °¢ ºÐ¾ßº°·Î ¿¬¼ö°­Á¸¦ °³ÃÖÇØ ¿À°í ÀÖ½À´Ï´Ù.
À̹ø 2007³âµµ Á¦13Â÷ Ç÷¾×Á¾¾çÇÐ ¿¬¼ö°­Á¿¡¼­´Â "Hematology 2007: State-of-the-Art Review " ¶ó´Â ÁÖÁ¦·Î ±Þ¼ÓÇÑ ¼Óµµ·Î ¹ßÀüÇÏ°í ÀÖ´Â Ç÷¾×Á¾¾çÇÐ ºÐ¾ß¿¡ ´ëÇÑ ÃֽŠÁö°ßÀ» ³íÀÇÇÏ°íÀÚ ÇÕ´Ï´Ù. º» °­Á´ Ç÷¾×Á¾¾çÇп¡ °ü½ÉÀ» °¡Áø ¸ðµç ºÐµé²² Å« µµ¿òÀÌ µÉ °ÍÀ¸·Î È®½ÅÇÏ´Â ¹ÙÀ̸ç, ¸¹Àº Âü¿©¿Í È°¹ßÇÑ ÅäÀǸ¦ ±â´ëÇÕ´Ï´Ù.

2007³â 2¿ù
¼­¿ï´ëÇб³º´¿ø ³»°ú°úÀå ¹Ú ¿µ ¹è
Ç÷¾×Á¾¾çºÐ°úÀå ¹æ ¿µ ÁÖ

-Á¦¸ñ: Hematology 2007: State-of-the-Art Review
-ÀϽÃ: 2007³â 4¿ù 6ÀÏ(±Ý) 11:30 – 18:50
-Àå¼Ò: ¼­¿ï´ëÇб³ ¾Ï¿¬±¸¼Ò »ï¼º¾Ï¿¬±¸µ¿ ´ë°­´ç
-´ë»ó: Ç÷¾×Á¾¾çÇÐ °ü·Ã ³»°ú, ¼Ò¾Æ°ú, Áø´Ü°Ë»çÀÇÇаú Àü¹®ÀÇ, °³¿øÀÇ, ÀüÀÓÀÇ, Àü°øÀÇ, °£È£»ç
-¿¬¼öÆòÁ¡:
´ëÇÑÀÇ»çÇùȸ 4ÆòÁ¡
´ëÇѳ»°úÇÐȸ Ç÷¾×Á¾¾ç³»°ú ºÐ°úÀü¹®ÀÇ 5ÆòÁ¡
-¹®ÀÇ»çÇ× ¾È³» ¹× ¿¬¶ôó:
110-744 ¼­¿ï½Ã Á¾·Î±¸ ¿¬°Çµ¿ 28 ¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú
ÀüÈ­: 02-2072-3981 Fax: 02-3673-2227, E-mail: hmo_snuh@yahoo.co.kr
-¼ö°­·á: (±³ÀçÁ¦°ø)
»çÀüµî·Ï : 3¸¸¿ø (ÀüÀÓÀÇ/Àü°øÀÇ/°£È£»ç : 2¸¸¿ø)
ÇöÀåµî·Ï : 4¸¸¿ø (ÀüÀÓÀÇ/Àü°øÀÇ/°£È£»ç : 3¸¸¿ø)
*»çÀü µî·Ï ¸¶°¨Àº 3¿ù 25ÀÏÀ̸ç FAX 02-3673-2227 ¶Ç´Â ¼­¿ï´ëº´¿ø Ç÷¾×Á¾¾ç³»°ú ȨÆäÀÌÁö(http://hmo.snuh.org)¸¦ ÅëÇÏ¿© µî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù.


*»çÀü µî·Ï½Ã ½ÅûÀÎÀÇ ¼º¸íÀ» ÇÊÈ÷ ±âÀÔÇϽðí, ¾Æ·¡ÀÇ ÀºÇà°èÁ·ΠÀԱݽÃÄÑ ÁֽʽÿÀ. Âü°¡ºñ´Â »çÀüµî·Ï 3¸¸¿ø, ÇöÀåµî·Ï 4¸¸¿øÀÔ´Ï´Ù.
(ÀüÀÓÀÇ, Àü°øÀÇ´Â 2¸¸¿ø / 3¸¸¿ø)
*¿¹±ÝÁÖ: ¹æ¿µÁÖ, ½ÅÇÑÀºÇà: ¿¬°Çµ¿ÁöÁ¡, °èÁ¹øÈ£: 367-04-934598

- ÀÏÁ¤Ç¥
12:00 registration

12:55 - 1:00 opening remark


1ºÎ ÁÂÀå: ¹Ú¼±¾ç (¼­¿ïÀÇ´ë)

1:00 - 1:20 Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia : À̱ÔÇü (¼­¿ï¾Æ»êº´¿ø)
1:20 - 1:40 Treatment of Acute Promyelocytic Leukemia : Çö¸í¼ö (¿µ³²ÀÇ´ë)
1:40 - 2:00 Updates in the Management of Patients with MDS : ±èÇüÁØ (Àü³²ÀÇ´ë)
2:00 - 2:20 Discussion


2ºÎ ÁÂÀå: ȲÅÂÁÖ (Àü³²ÀÇ´ë)

2:20 - 2:40 Defining and Managing Imatinib Resistance in CML: ¹Ú¼±¾ç (¼­¿ïÀÇ´ë)
2:40 - 3:00 New Strategies for the Treatment of AML Including Antibodies and Other Novel Agents : ¹ÎÀ¯È« (¿¬¼¼ÀÇ´ë)
3:00 - 3:20 The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia : ÁÖ¿µµ· (ÀÎÁ¦ÀÇ´ë)
3:20 - 3:40 Discussion

3:40 - 4:00 ÈÞ½Ä


3ºÎ ÁÂÀå: ±èö¼ö (ÀÎÇÏÀÇ´ë)

4:00 - 4:20 Therapies for Relapsed Hodgkin Lymphoma: ÀÌÁ¾¼® (¼­¿ïÀÇ´ë)
4:20 - 4:40 Non-Hodgkin Lymphoma: Risk Stratification and Management of Relapsed Disease : ±èö¼ö (ÀÎÇÏÀÇ´ë)
4:40 - 5:00 An Update of the Management of Multiple Myeloma : À±¼º¼ö (¼­¿ïÀÇ´ë)

5:00 - 5:20 Discussion

4ºÎ ÁÂÀå: ±èº´±¹ (¼­¿ïÀÇ´ë)

5:20 - 5:40 Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation : ±èÀÎÈ£ (¼­¿ïÀÇ´ë)
5:40 - 6:00 Umbilical Cord Blood Transplantation : ±¸È«È¸ (¼º±Õ°üÀÇ´ë)
6:00 - 6:20 Haploidentical Stem Cell Transplantation : ±èÈñÁ¦ (°¡Å縯ÀÇ´ë)

6:20 - 6:40 Discussion

6:40 - 6:50 Closing remark : ±èº´±¹ (¼­¿ïÀÇ´ë)